Medical Equipment News
-
Daxor Corporation to Commence Trading on the Nasdaq Capital Market
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that it will commence trading on The Nasdaq Capital Market effective at the opening of trading on February 2, 2022, transferring the listing of its common stock from the New York Stock Exchange – American. Daxor’s common stock will continue trading under the ticker symbol ...
-
Hebei biomaterials plant selects Siveco China for Asset Maintenance Management project
Hebei CASDA Biomaterials Co., Ltd., part of specialty materials leader Arkema Group, has selected Siveco China to implement its Maintenance 4.0 solution for Asset & Maintenance Management. The decision was made after a comprehensive selection process and careful consideration of various suppliers. Established in January 2010, Hebei CASDA Biomaterials Co., Ltd. joined Arkema Group in January ...
By Siveco
-
CD Formulation: A Leading Manufacturer of Excipients for Pharmaceutical Preparation
Excipients are of vital importance in the process of drug development. A good choice of excipient can lead to the formulation of stable dosage forms. To better meet the increasing demand for excipients, CD Formulation supplies a wide range of excipients for different research purposes, including binders, lubricants, diluents, disintegrants, emulsifiers, plasticizers, surfactants, sweeteners, ...
-
Creative Enzymes Offers the Raw Materials for Sialic Acid Assay Kit Manufacture
Creative Enzymes, the world’s leading diagnostic enzyme production company, has been committed to providing customers with various enzyme products and services for medical and research diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has gained a solid reputation. Recently, Creative Enzymes announced the raw ...
-
U.S. FDA approves Xarelto to treat venous thromboembolism (VTE) and to prevent VTE in children
Xarelto is the only Factor Xa anticoagulant FDA approved for pediatric patients and offers a flexible weight-based dosing Xarelto is available in both oral tablet and liquid suspension formulations for use in appropriate children less than 18 years of age Convenient liquid formulation advances standard of care for children; alleviates administration challenges found with injectable ...
By Bayer AG
-
Thermo Fisher Scientific Updates TaqMan SARS-CoV-2 Mutation Panel to Enable Direct Identification of Omicron Variant
Thermo Fisher Scientific, the world leader in serving science, today announced an update to its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel to enable direct detection of the Omicron SARS-CoV-2 variant. The panel is designed with a customizable menu of real-PCR genotyping assays to accurately identify known SARS-COV-2 variants in just over an hour. South African researchers first ...
-
Bayer receives positive CHMP opinion for finerenone as a new treatment for adult patients with chronic kidney disease associated with type 2 diabetes
Finerenone, a non-steroidal, selective mineralocorticoid receptor (MR) antagonist, is recommended by CHMP for marketing authorization for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) CHMP opinion is based on the results of the Phase III FIDELIO-DKD study investigating the efficacy and safety of finerenone on kidney and cardiovascular outcomes in patients ...
By Bayer AG
-
Makya Webinar 2021
Topic: Makya: AI-driven de novo drug design and multi-parametric optimisation Recording Duration: 56:50 Webinar Start Time: Dec 7, 2021, 10 - 11 AM CET & 5 - 6 PM CET Access to the Recorded ...
By Iktos
-
Spaya Webinar: 2021
Webinar on Spaya: AI-Enhanced Retrosynthesis for Chemists ...
By Iktos
-
Phase III trial with Nubeqa (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
ARASENS trial demonstrates an increase in overall survival evaluating darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT, a standard of care in metastatic hormone-sensitive prostate cancer (mHSPC) / Bayer plans to present these pivotal data at a forthcoming scientific congress and to discuss them with health authorities / ARASENS is ...
By Bayer AG
-
Daxor Corporation Presents New Data Validating the Benefit of the BVA-100 Blood Test for Optimal Heart Failure Management at Key Scientific Society Meeting
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 blood test in identifying heart failure patient-specific phenotypes and detecting true anemia. These data from two separate studies were presented at the American Heart Association (AHA) Scientific Sessions virtual meeting from ...
-
Bayer extends clinical development program for finerenone with Phase III study in children and adolescents with chronic kidney disease
For children and adolescents with chronic kidney disease (CKD), as for adults, the unmet need is high for new treatments to delay disease progression and preserve kidney function / The Phase III study FIONA will investigate the effect of finerenone in pediatric patients with CKD and severely increased proteinuria Bayer announced today the initiation of the FIONA study, a multicenter, randomized, ...
By Bayer AG
-
Major Research Findings Highlight Effectiveness of the PrecivityAD™ Blood Test That Clinicians Use to Aid in Alzheimer’s Disease Diagnosis
Four separate research reports presented at premier Alzheimer’s disease and aging conferences add to the increasing set of details about the accuracy and clinical usefulness of the PrecivityAD™ blood test from C2N Diagnostics. The PrecivityAD™ test is a breakthrough blood test intended for use in patients with cognitive impairment. The test helps physicians determine the ...
-
New Phase III study to investigate expanded use of vericiguat in patients with chronic heart failure with reduced ejection fraction
New Phase III study VICTOR will assess vericiguat efficacy and safety in patients who have not had a recent worsening heart failure event / VICTOR expands upon the Phase III VICTORIA study, providing further insight into the use of vericiguat in a broader range of patients with chronic heart failure with reduced ejection fraction Bayer and its development partner MSD (a tradename of Merck & ...
By Bayer AG
-
New IVD System Enables Assay Developers and Clinical Laboratories to Accelerate Molecular Diagnostics Growth
As assay developers and clinical testing laboratories consider next steps for molecular diagnostics post-pandemic, a new in vitro diagnostic (IVD) system from Thermo Fisher Scientific will enable them to expand their assay menus and IVD testing capabilities moving forward. The Applied Biosystems QuantStudio 7 Pro Dx Real-Time PCR System is a compact instrument that easily transitions from ...
-
New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100) Diagnostic in Neurocritical Care
Data Highlight Daxor’s Diagnostic Changes Care in 69% of Patients With Non-Traumatic Subarachnoid Hemorrhage (nSAH) Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility of the BVA-100 blood test in patients with non-traumatic subarachnoid hemorrhage (nSAH) presented at the virtual ...
-
New data from finerenone clinical trial program reinforces renal and cardiovascular benefits in patients with CKD and T2D independent of baseline therapy
Exploratory analysis of the FIGARO-DKD study with finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, indicated a reduction in renal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as seen in the FIDELIO-DKD study Analysis of the FIDELIO-DKD study highlighted that early reduction of urine albumin-to-creatinine ratio (UACR) with ...
By Bayer AG
-
InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced that results from the investigator-initiated SIBERIA randomized clinical trial of CGuard EPS, that evaluated the peri-procedural and 30-day silent brain infarcts associated with the use of its ...
-
Thermo Fisher Scientific Showcases Investment and Innovation During CPhI Worldwide 2021
At CPhI Worldwide 2021, Thermo Fisher Scientific will showcase its newest capabilities across its global pharma services network which help pharmaceutical and emerging biotech companies accelerate time to market in a wide range of modalities and platforms including cell and gene therapies, drug products and biologics. CPhI 2021 begins with a virtual conference through November 5, 2021 and an ...
-
European Patent Office maintained Bayer patent on the once-daily administration of rivaroxaban (Xarelto)
The European Patent Office has reversed a first instance decision and maintained a Bayer patent (EP 1 845 961) on the once-daily administration of rivaroxaban (Xarelto™; 10, 15 and 20 mg). The 2.5 mg dose is not affected. Several generic drug manufacturers had initially successfully opposed the patent. With this decision of the European Patent Office, this patent is still valid until ...
By Bayer AG
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you